

INTERVIEW WITH DR. STEVEN CARR FROM THE BROAD INSTITUTE ON PROTEOMICS FOR PERSONALIZED MEDICINE

The Measure of Confidence

In this podcast interview with Agilent Technologies, Dr. Carr discusses how proteomics is used in biology and the implications for personalized medicine. He also discusses the incredible results his lab has had with Agilent's automation solutions and the future he sees for mass spectrometry as a critical technology in the lab.

Dr. Carr uses the Agilent Bravo Automated Liquid Handling Platform and Agilent AssayMAP technology for his research.

Dr. Steven Carr is director of Proteomics at the Broad Institute of MIT and Harvard. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology and medicine. Dr. Carr and his group collaborate with scientists across the Broad Institute, Harvard University, Harvard Medical School, and the 17 Harvard-affiliated hospitals. Research in his lab focuses on detecting and quantifying modifications in the proteome, as well as developing new technologies to quantify proteins in cells and biological fluids with a high degree of specificity.

Listen to the podcast now!



Steven Carr, Ph.D.
Director of Proteomics at the Broad
Institute of MIT and Harvard

Listen to the podcast now at:
[http://www.bioanalysis-zone.com/
articles/agilent_podcast_drsteven-
carr/](http://www.bioanalysis-zone.com/articles/agilent_podcast_drsteven-carr/)

